Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
BioSpace1d
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...
Medpage Today on MSN3d
Sodium Channel Blocker Relieves Acute Pain in Phase III Data
An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to ...
Vertex Pharmaceuticals: Strategic Growth and Promising Drug Development Drive Buy Rating
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating on October 17. Jessica Fye has given ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Non-Opioid Solution to Acute Pain Management
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
The Pharma Letter3d
Vertex says Phase III data highlight suzetrigine’s potential
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly ...
BioSpace3d
Vertex Unveils Full Phase III Data for Non-Opioid Pain Candidate, Touts Safety Profile
BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental ...
FierceBiotech3d
Vertex posts full pain data ahead of FDA ruling, unpacking combo results, Vicodin miss and stellar safety
Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid ...
The Pharma Letter4d
Gilead and Merck tout first weekly oral HIV treatment
US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...
Business Wire6d
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on ...
Le Lézard6d
The Standard Group Elevates Printing Services with the New Fuji J Press 750
The Standard Group, a leading provider of enterprise print, promo, and mail solutions, proudly announces the installation of the cutting-edge Fuji J Press 750. This strategic investment enhances The ...
Le Lézard6d
The Nora Project Supports Caregivers in Raising Kids Who Include
The Nora Project, a nonprofit committed to building inclusive classrooms, will host a fall training to provide practical, actionable advice and strategies for supporting kids as they develop the ...